Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Brazikumab | Whole mAb | G2 | Lambda | Phase-III | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS | QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVL | na | na | null | null | null | 2,016 | 2017 | IL23A | Allergan;Amgen;AstraZeneca | na | Crohn's disease;Ulcerative colitis | Psoriasis | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNE YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDRGYTSSWYPDA FDIW GQG TMVTVS S | QSVLTQPPSVSGAPGQ RVTISCT GSSSNTGAG YDVHWYQQ VPGTAP KLLIYG SGNRPSGVPDRFSGSKSGTS ASLAIT GLQAEDEAD YYCQS YDSSLSG WVF GGGT RLTV L |
Bremzalerbart | Whole mAb | G4 | Kappa | TBC | Active | QVQLQESGPGLVKPSETLSLTCSVSGGSITNYFWTWIRQSPGKGLEWIGYIYYSGGTNYNPSLKSRVTISIDTSKNQFSLNMNSVTAADTAVYYCAGSYYYGVDVWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSIKSFLAWYRQKPGQAPRLLIYDASNRPTGIPARFSGSGSGTDFTLTINSLESEDFAVYFCQQRNNWPFTFGPGTKVDIK | na | na | 7mxl:JK/7n0v:HL | null | null | 2,022 | na | Bet Pollen Antigen 1 | TBC | TBC | TBC | TBC | TBC | Identical V region sequence to Atisnolerbart | QV QLQE SGPGL V KPSE TLSLTCSV SGGS ITNYFWTWIR QSPGKGL EWIGYIYYS GGTNYNPSLK SRVTISID TSKN QFSLNM NSVTAADT AVYYC AGS YYYGVDVW GQG TTVTVS S | E IVLT QSPA TLSL SPGE RATLSCR AS QSIKSFLAWYR QKPGQAP RLLIYD ASNRPTGIP ARF SGSGSGT DFTLTIN SLESED FAVYFCQ QRNNWPF T FGPGT KVDI K |
Brentuximab | Whole mAb ADC | G1 | Kappa | Approved | Active | QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA | DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK | na | na | null | null | null | 2,010 | 2011 | TNFRSF8 | Bristol-Myers Squibb;Celgene Corporation;Dana-Farber Cancer Institute;Fondazione Italiana Linfomi;Fox Chase Cancer Center;Immune Tolerance Network;Lymphoma Academic Research Organisation;Massachusetts General Hospital;National Cancer Institute (USA);National Institute of Allergy and Infectious Diseases;Seattle Genetics;Stanford University;Takeda;Takeda Oncology;UNC Lineberger Comprehensive Cancer Center;Washington University School of Medicine | Anaplastic large cell lymphoma;Cutaneous T-cell lymphoma;Hodgkin's disease;Mycosis fungoides;T-cell lymphoma | Adult T-cell leukaemia-lymphoma;Diffuse large B cell lymphoma;Germ cell and embryonal neoplasms;Mastocytosis;Mesothelioma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Sezary syndrome;Diffuse scleroderma | Graft-versus-host disease;Leukaemia;Multiple myeloma;Solid tumours;Systemic lupus erythematosus | na | null | Q IQLQ QSGPE VV KPGA SVKISCK ASGY TFTDYYITWVK QKPGQG LEWIGWIY PGSGNTKYNEKFKG KATLTVD TSSST AFMQLS SLTSEDT AVYFCA NYGN YWFAYW GQGT QVTVS A | D IVLT QSPA SLAVS LGQ RATISCK ASQ SV DFDGD SYMNWYQ QKPGQPP KVLIYAA SNLESGIP ARFS GSGSGTD FTLNIHP VEEEDA A TYYCQ QSNEDPWTFGGGT KLEI K |
Briakinumab | Whole mAb | G1 | Lambda | Preregistration (w) | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS | QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL | na | na | 5n2k:LK:BA:PO:DC:NM:FE/5njd:RQ:TS:XW:VU:PO:NM | null | null | 2,009 | 2010 | IL12B | Cambridge Antibody Technology;Abbott GmbH & Co. KG | na | na | Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAFIRY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCKT HGSHDNWGQG TMVTVS S | QSVLTQPPSVSGAPGQ RVTISC SGSRSNIGSN TVKWYQQ LPGTAP KLLIYY NDQRPSGVPDRFSGSKSGTS A SLAI TGLQAEDEAD YYCQS YDRYTHP ALLF GTGT KVTV L |
Briquilimab | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCRASESVDIYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPYTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | KIT | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGVIYS GNGDTSYNQ KFKGRVTITA DKSTS TAYMELSS LRSEDT AVYYCARE RDTRFGNWGQ GTLVTVS S | D IVMT QSPDS LAVS LGER ATINCR ASE SVDIY GNS FMHWYQ QKPGQPP KLLIYLA SNLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNNEDPY T FGGG TKVEI K |
Brodalumab | Whole mAb | G2 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK | na | na | null | null | null | 2,011 | 2012 | IL17RA | Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma | Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis | Axial Spondylarthritis;Systemic scleroderma;Palmoplantar pustulosis | Asthma;Crohn's disease;Rheumatoid arthritis | Abgenix XenoMouse | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTRYGISWVRQ APGQGL EWMGWISTY SGNTNY AQKL QG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RR QLYFDY WGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSNL AWFQ QKPGQAPRP LIYD ASTRATGVP ARFS GSGSGTD FTLTISS LQSED FAVYYCQQ YDNWP LTF GGG TKVEI K |
Brolucizumab | scFv | na | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEWVGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLDIWGQGTLVTVSS | EIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVL | na | na | null | null | null | 2,014 | 2015 | VEGFA | ESBATech;Alcon | Wet age-related macular degeneration | Diabetic macular oedema;Retinal vein occlusion;Diabetic retinopathy | na | na | null | E VQLVES GGG LV QPGG SLRLSCT ASGFSLTD YYYMTWVRQ APGKG LEWVGFI DPDDDPY YATW AKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC AGGDHNSGW GLDIW GQG TLVTVS S | E IVMT QSPS TLSAS VGD RVIITC Q ASEIIHSWLAWYQ QKPGKAP KLLIYLA ST LASGVPS RF SGSGSGA EFTLTISS LQPDDF ATYYCQNVYLAS TNGANFGQGT KLTV L |
Brontictuzumab | Whole mAb | G2 | Lambda | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS | QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAPRTLIGGTNNRAPGVPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNHWVFGGGTKLTVL | na | na | null | null | null | 2,014 | 2015 | NOTCH1 | OncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center | na | na | Adenoid cystic carcinoma;Solid tumours;Haematological malignancies;Colorectal cancer | na | null | Q VQLVQ SGA EVK KPGA SVKISCKV SG YTLRGYWIEWVR QAPGKG LEWIGQI LPGTGRTNYNEKFKG RVTMTA DTSTDT AYMELSS LRSEDT AVYYCARF DGNY GYYAMDY WGQG TTVTVS S | QA VVT QEP SLTV SPGG TVTLTCR SSTGA VTT SN YANWF QQKPGQAPR TLI GGTNNRAPGVPA RFS G SL LGGK AALTL SGAQPEDEA EYYCALWY SNH WVF GGGT KLTV L |
Budigalimab | Whole mAb | G1 | Kappa | Phase-II | Active | EIQLVQSGAEVKKPGSSVKVSCKASGYTFTHYGMNWVRQAPGQGLEWVGWVNTYTGEPTYADDFKGRLTFTLDTSTSTAYMELSSLRSEDTAVYYCTREGEGLGFGDWGQGTTVTVSS | DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSHGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPVTFGQGTKLEIK | na | na | null | null | null | 2,018 | 2019 | PDCD1 | AbbVie | na | Colorectal cancer;Ovarian cancer;Small cell lung cancer;Solid tumours;Endometrial cancer;Fallopian tube cancer;HIV-1 infections;Peritoneal cancer;Squamous cell cancer | na | na | null | E IQLVQ SGA EVK KPGS SVKVSCK ASGY TFTHY G MNWVR QAPGQGL EWVGWVN TYTGEPT Y ADDFKG RLTFTLD TSTS TAYMELS SLRSEDT AVYYCTR EGEGLGFGDWGQG TTVTVS S | DV VMT QSPLSLPVTPGEPA SISC RSSQ SIVHS HGD TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSH IPVTF GQGT KLEI K |
Burfiralimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYNMNWVRQAPGKGLEWMGNIDPYYGSDTYAQKFQGRVTMTVDKSISTAYMELSRLRSDDTAVYYCARETGTRAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASENIYSNLAWYQQKPGKAPKLLIYVADNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHFYGSPRTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | VIM | ImmuneMed | na | COVID-19 Pneumonia;Pneumonia;Hepatitis B;Alcholic hepatitis;Non-alcoholic steatohepatitis;Psoriasis;Scleroderma | na | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYNMNWVR QAPGKGL EWM GNIDPYYGSDTY AQ KF QG RVTMTV DKSI STAYMELSR LRSDDT AVYYCAR ETGTRA M DYWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASENIYSN LAWY QQKPGKAP KLLIYVA DNLADGVPS RF SGSGSGTD FTLTIS SLQ PEDFATY Y CQH FYGSPRTFGGGT KVEI K |
Burosumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIK | na | na | null | null | null | 2,016 | 2017 | FGF23 | Kyowa Hakko Kirin;Ultragenyx Pharmaceutical | X-linked dominant hypophosphataemic rickets;Osteomalacia | Nevus | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT NH YMHWVRQ APGQGL EWMGII NPISGSTSNAQ KFQGRVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RD IVDAF DFWGQG TMVTVS S | AI QLT QSPSS LSAS VGD RVTITCR ASQGIS SALVWYQ QKPGKAP KLLIYD ASSLESGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNDY FTF GPGT KVD IK |
Cabiralizumab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2016 | CSF1R | Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University | na | Pancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours | Rheumatoid arthritis | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF TDN YMIWVRQ APGQG LEWMGD INPYNGGTT F NQK F KG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RESPYFS NLYVMD YWGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCK ASQ SV DYDGDNY MNWYQ QKPGQAP RLLIYAA SNLESGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCHL SNEDLSTFGGG TKVEI K |
Cadonilimab | Bispecific Mixed mAb and scFv | G1;na | Kappa;Lambda | Approved | Active | QVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA | DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK | QVVLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | PDCD1;CTLA4 | Akeso Biopharma | Cervical cancer | Non-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma | na | na | (June '22: Corrected FWH1 and FWL2 sequences) | Q VQLVE SGA EVK KPGA SVKVSCK ASGY SFTGYTMNWVR QAPGQ CLEWIGLI NPYNNITN YAQ KFQG RVTFTV DTSIS TAYMELSRL RSDDTG VYFCARLD YRSYWGQG TLVTVS A | DIQ MT QSPSSM SA SVGD RVTFTCR ASQD INTYLSWFQ QKPGKSPK TLIYRA N RLV SGVPS R FSGSGSGQD YTLTISS LQPEDM A TYYCLQ YDEFP LTF GAGT KLEL K |
Calpurbatug | Whole mAb | G1 | Kappa | TBC | Active | QSQVQLVESGPGLVKPSETLSLTCRVSGDSNRPSYWSWIRQAPGKAMEWIGYVYDSGVTIYNPSLKGRVTISLDTSKTRFSLKLTSVIAADTAVYYCARERFDRTSYKSWWGQGTQVTVSS | DIVLTQAPGTLSLSPGDRATLSCRASQRLGGTSLAWYQHRSGQAPRLILYGTSNRATDTPDRFSGSGSGTDFVLTISSLEPEDFAVYYCQQYGSPPYTFGQGTTLDIK | na | na | null | null | null | 2,022 | na | Bacteria Proteins HU and IHF | TBc | TBC | TBC | TBC | TBC | Conserved epitopes on HU (histone-like protein) and IHF (integrin host factor) | QS QVQLVES GPGL V KPSE TLSLTCRVS GDSNRPS YWSWIR QAPGKA MEWIGYVY DSG VTIY NPSLKG RVTISL DTSKT RFSLKLTSVIA ADT AVYYCARE RFDRTSYKSWWGQG TQVTVS S | D IVLTQ APG TLSL SPGDR ATLSCRA SQRLGGT SLAWYQH RSGQAP RLILYG TSNRATDTPDRFSGSGSGT DFVLTIS SLE PEDFA VYY CQQ YGSPPYTFGQGT TLD IK |
Camidanlumab | Whole mAb ADC | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYIINWVRQAPGQGLEWMGRIIPILGVENYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARKDWFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK | na | na | null | null | null | 2,017 | 2018 | IL2RA | ADC Therapeutics;Genmab | na | Hodgkin's disease;Non-Hodgkin's lymphoma;Solid tumours | Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSRYIINWVR QAPGQGL EWMGRIIPIL GVEN YAQ KFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RKDWFDYWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSSYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGTD FTLTIS RLE PEDFA VYY CQQ YGSSPL TF GGGT KVEI K |
Camoteskimab | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSISADGYYWSWIRQPPGKGLEWIGSLYYSGSTYYNPSLKGRVTISGDTSKNQFSLKLSSVTAADTAVYYCARTPAYFGQDRTDFFDVWGRGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSHHPPWTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | IL18 | Avalo Therapeutics;MedImmune | na | Adult-onset Still's disease;Juvenile rheumatoid arthritis | Chronic obstructive pulmonary disease;Multiple myeloma | na | null | Q VQLQE SGPGL V KPSE TLSLTCTV SGG SI SADG YYWSWIR QPPGKGL EWIGSLYY SGS TYY NPSLK GRVTIS GDTSKN QFSLKLSS VTAADT AVYYCA RTPAYFGQDRTD FFDVW GRG TLVTVS S | DIQ MT QSPS TLSAS VGD RVTITCR ASQGI SSW LAWY QQKPGKAP KVLIYK ASTLESGVPS R FSGSGSGT EFTLTISS LQPDDF ATYYCQ QSHHPPWTFGQGT KLEI K |
Camrelizumab | Whole mAb | G4 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | PDCD1 | Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University | Hodgkin's disease | Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Biliary cancer;Cervical cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gastric cancer;Osteosarcoma;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Urogenital cancer;Diffuse large B cell lymphoma;Breast cancer;Malignant melanoma | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYMMSWVR QAPGKG LEWVATIS GGGANT Y YPDSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA R QLYYFD YWGQG TTVTVS S | DIQ M TQSPSS LSA SVGD RVTITCL ASQTIG TWLTWYQ QKPGKAP KLLIYTAT SLADGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQQVYSI PW T FGGG TKVEI K |
Canakinumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS | EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK | na | na | null | 4g5z:HL/5bvj:HG:FE:BA:DC/4g6j:HL/5bvp:HL | null | 2,007 | 2008 | IL1B | Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich | Adult-onset Still's disease;Cryopyrin-associated periodic syndromes;Familial autosomal dominant periodic fever;Familial Mediterranean fever;Gouty arthritis;Juvenile rheumatoid arthritis;Peroxisomal disorders | Cardiovascular disorders;Behcet's syndrome;Non-small cell lung cancer;Abdominal aortic aneurysm;Atherosclerosis;Malignant melanoma;Osteoarthritis;Peripheral arterial occlusive disorders;Pulmonary sarcoidosis;Schnitzler syndrome;Sickle cell anaemia;Breast cancer;Pancreatic cancer;Renal cell carcinoma | Chronic obstructive pulmonary disease;Asthma;Diabetic retinopathy;Polymyalgia rheumatica;Rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus | Medarex UltiMAb Mouse | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSVYGMNWVR QAPGKGL EWVAIIWY DGDNQ YYAD SVKG RFTISR DNSKN TLYLQM NGLRAEDT AVYYCAR DLRTGPFDYWGQG TLVTV SS | E IVLTQ SPDFQSVTPKE KVTITCR ASQSIGS SLHWYQ QKPDQSP KLLIKYA SQSFSGVPSRFSGSGSGT DFTLTIN SLEAED AAA YYC HQSSSLP FTF GPGT KVDI K |
Cantuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGETVKISCKASDYTFTYYGMNWVKQAPGQGLKWMGWIDTTTGEPTYAQKFQGRIAFSLETSASTAYLQIKSLKSEDTATYFCARRGPYNWYFDVWGQGTTVTVSS | DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK | na | na | null | null | null | 2,003 | 2004 | MUC1 | ImmunoGen;GlaxoSmithKline | na | na | Gastric cancer;Solid tumours | na | null | Q VQLVQ SGA EVK KPGE TVKISCK ASDY TFTYYGMNWVK QAPGQG LKWMGWID TTTGEPT YAQKF QG RIAFSLE TSAST AYLQIKSL KSEDT ATYFCAR RGPYN WYFDV WGQG TTVTVS S | D IVMT QSPLSVPVTPGEP VSISCR SSK SLLH SNGN TYLYWFLQ RPGQSP QLLIYRM SNLVSGVPDRFSGSGSGT AFTLRISRVE AEDV GVYYCLQH LEYPF TF GPGT KLEL K |
Caplacizumab | Nanobody | na | na | Approved | NFD | EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS | na | na | na | 7a6o:B/7eow:B | null | null | 2,011 | 2012 | VWF | Ablynx | Thrombotic thrombocytopenic purpura | na | Thrombosis | Nanobody Technology | null | E VQLVES GGG LV QPGG SLRLSC AASGR TFSY NPMGW FR QAPGKGR ELVAAIS RTGGSTYYPDSV EGRFTIS RDNAK RMVYLQM NSLRAEDT AVYYCAA AG VR AEDGR VRT LPSE YTFW GQG TQVTVS S | null |
Carlumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK | na | na | null | 4dn3:HL/4dn4:HL | null | 2,010 | 2011 | CCL2 | MorphoSys;Janssen Biotech | na | na | Idiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours | Human Phage Display | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYGISWVRQ APGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCAR YDGI Y G ELDFW GQG TLVTVS S | E IVLT QSPA TLSL SPGE RATLSCR ASQSVS DAYLAWYQ QKPGQAP RLLIYD ASSRATGVP ARFS GSGSGT DFTLTIS SLEPE D FAVYYC HQ YIQLHSFTF GQGT KVEI K |
Carotuximab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS | QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK | na | na | null | null | null | 2,015 | 2016 | ENG | National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute | na | na | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma;Wet age-related macular degeneration | na | null | E VKLEE SGGG LV QPGGS MKLSC AASGFTFS DAWMDWVRQ SPEKGL EWVAEIRS KASNHA TYYAES VKG RFTISR DDSKS SVYLQMN SLRAEDTG IYYCTRWRRFF DSWGQG TTLTVS S | Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYMHWYQ QKPGSSPKP WIYAT SNLASGV PVRFS GSGSGT SYSLTISRVE AEDA ATYYCQQ WSSNPL TF GAGT KLEL K |
Casdozokitug | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFRSYGMNWVRQAPGKGLEWVSGISSSGSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGGRTSYTATAHNWFDPWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLFSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHASAPPTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | IL27 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFRSY GM NWVR QAPGKG LEWVSGI SSSGS YIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAED TAVYYCA RDGGR TSYTATA HN WF DPWGQ GTLVTVS S | D IVMT QSPDS LAVS LGE RATINC KSSQ SVLFS SNNKN YLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QHASAPPTFGGG TKVEI K |
Cemiplimab | Whole mAb | G4 | Kappa | Approved | Active | EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR | na | na | null | null | null | 2,018 | 2019 | PDCD1 | Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center | Squamous cell cancer;Basal cell cancer;Non-small cell lung cancer | Cervical cancer;Oropharyngeal cancer;Prostate cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Ovarian cancer;Peritoneal cancer;Solid tumours;Head and neck cancer;Malignant melanoma;Renal cell carcinoma | B-cell lymphoma | na | null | E VQLLE SGG VLV QPGG SLRLSC AASGF TF SNFG MTWVRQ APGKG LEWVSG ISGGGRD TYFA DSVKG RFTISR DNSKN TLYLQMN SLKGEDT AVYYCVK WGN IYFDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD SITITCRAS LS INTFLNWYQ QKPGKAPN LLIYAA SSLHGGVPSRFSGSGSGTD FTLTIRT LQ PEDFA TYYCQ QSSNTPF TF GPGT VVDF R |
Cendakimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVTLRESGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIYYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTISCRASQDIRNYLNWYQQKPGKAPKLLIFYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQGNTLPLTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | IL13 | Abbott Laboratories;AbbVie;Receptos | na | Eosinophilic oesophagitis | Allergic asthma | na | null | E VTLRE SGPGLVKPTQ TLTLTCTLYGFSL STSDMG VDWIR QPPGKGL EWLAHIW WDDVKR YNPALK SRLTISK DTSKN QVVLKLTS VDPVDT ATYYCARTV SSG YIYYAMD YWGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTISCR AS QDIRNYLNWYQ QKPGKAP KLLIFYT SKLHSGVPSRFSGSGSGTD YTLTIS SLQ PEDIATY Y C QQGN TLPLTF GGGT KVEI K |
Cergutuzumab | Whole mAb Fusion | G1 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2016 | CEACAM5 | Roche | na | na | Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTEFGMNWVR QAPGQG LEWMGWIN TKTGE ATYVEEF KG RVTFTT DTSTS TAYMELRSL RSDDT AVYYCAR WDF AYYVEAM DYWGQG TTVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASAAVG TYVAWYQ QKPGKAP KLLIYSASY RKRGVPS RF SGSGSGTD FTLTIS SLQPE DFA TYYC HQ Y Y T YP LFTF GQGT KLEI K |
Certolizumab | Fab | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK | na | na | 5wuv:HL/5wux:HL:AB:CD | null | null | 2,004 | 2004 | TNFA | UCB | Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis | Interstitial cystitis;Juvenile rheumatoid arthritis | Cognition disorders | na | null | E VQLVES GGG LV QPGG SLRLSC AASG YVFT DYGM NWVR QAPGKGL EWMGWINTY IGEP IY ADSVKG RFTFSL DTSKS TAYLQMN SLRAEDT AVYYC ARGY RSYAMD YWGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCK ASQNVGT NVAWYQ QKPGKAPK ALIYSASFLY SGV PYRFS GSGSGTD FTLTIS SLQ PEDFATYYCQQ YNI YPLTF GQGT KVEI K |
Cetrelimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | PDCD1 | Janssen Research & Development | na | Multiple myeloma;Prostate cancer;Solid tumours;Urogenital cancer;Bladder cancer | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF DTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCA RPGL AAAY DTGSLDYWGQG TLVTVS S | E IVLT QSPA TLSL SPGE RATLSCR ASQS VRSYLAWYQ QKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLE PEDF AVYYC Q QRNYWP LT FGQGT KVEI K |
Cetuximab | Whole mAb | G1 | Kappa | Approved | Active | QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA | DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK | na | na | 6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC | 5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC | 5gz0:BA:DC/6arp:BA:DC/6aru:CB | 1,999 | 2000 | EGFR | Array BioPharma;Bristol-Myers Squibb;Celldex Therapeutics Inc;Centre Jean Perrin;Eli Lilly;Merck KGaA;New York University School of Medicine;Novartis;Pierre Fabre;Roche;University Hospital Ghent;University of California;University of Heidelberg;University of Michigan Comprehensive Cancer Center | Colorectal cancer;Head and neck cancer | Non-small cell lung cancer;Bladder cancer;Breast cancer;Gastric cancer;Mesothelioma;Rectal cancer;Squamous cell cancer;Adenoid cystic carcinoma;Oesophageal cancer | Pancreatic cancer;Prostate cancer | na | null | QV QLKQ SGPGLVQPSQ SLSITCTV SGF SL T N Y GVHWVRQ SPGKGL EWLGVIWS GGNTDYNTPF TSRLSI NKDNSKS QVFFKM NSLQSNDT AIYYCA RAL TYY D YEFAYW GQG TLVTVS A | DI LLT QSP VILSV SPGE RVSFSCR ASQSIGT NIHWYQQ RTNGSP RLLIKYA SESISGIPSRFSGSGSGT DFTLSIN SVES EDIADYYCQ QNNNWPTTFGAGT KLEL K |
Cevostamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-I | Active | EVQLVESGPGLVKPSETLSLTCTVSGFSLTRFGVHWVRQPPGKGLEWLGVIWRGGSTDYNAAFVSRLTISKDNSKNQVSLKLSSVTAADTAVYYCSNHYYGSSDYALDNWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVRNLVVWFQQKPGKAPKLLIYSGSYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSPPYTFGQGTKVEIK | EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWTSTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSFILRTFGQGTKVEIK | None;None | None;None | None;None | 2,019 | 2020 | FCRL5;CD3 | Genentech | na | Multiple myeloma | na | na | null | E VQLVE SGPGL V KPSE TLSLTCTV SGF SLTRFGVHWVR QPPGKGL EWLGVIWR GGSTDYN AAFVSRLTIS KDNSKN QVSLKLSS VTAADT AVYYC SNHYYGSSDY AL DNWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQDVR NLVVWFQ QKPGKAP KLLIYS GS YRY SGVPSRFSGSGSGTD FTLTISS LQP EDFAT YYC QQHYSPPY T FGQGT KVEI K |
Cibisatamab | Bispecific mAb with Domain Crossover | G1;G1 | Kappa;Lambda | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK | QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,017 | 2018 | CEACAM5&CD3E;CD3E | Roche | na | Non-small cell lung cancer;Colorectal cancer | Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTEFGMNWVR QAPGQG LEWMGWIN TKTGE ATYVEEF KG RVTFTT DTSTS TAYMELRSL RSDDT AVYYCAR WDF AYYVEAM DYWGQG TTVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASAAVG TYVAWYQ QKPGKAP KLLIYSASY RKRGVPS RF SGSGSGTD FTLTIS SLQPE DFA TYYC HQ Y Y T YP LFTF GQGT KLEI K |
Ciduvectamig | Bispecific mAb | G4;G4 | Kappa;Lambda | TBC | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVSVISGSGGFTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMPLNSPHDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPLTFGGGTKVEIK | QVQLQQSGPRLVRPSQTLSLTCAISGDSVFNNNAAWSWIRQSPSRGLEWLGRTYYRSKWLYDYAVSVKSRITVNPDTSRNQFTLQLNSVTPEDTALYYCARGYSSSFDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSNIGTYKFVSWYQQHPDKAPKVLLYEVSKRPSGVSSRFSGSKSGNTASLTISGLQAEDQADYHCVSYAGSGTLLFGGGTKLTVL | None;None | None;None | None;None | 2,022 | na | TMEFF2;CD3E | TBC | TBC | TBC | TBC | TBC | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYSMSWVR QAPGKG LEWVSVIS GSGGFTDYADSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCAR MPLNSPHDYWGQ GTLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAP KLLIYAA SSLQSGVPS RF SGSGSGTD FTLTISS LQPEDF ATYYCL QDYNYP LTF GGG TKVEI K |
Cifurtilimab | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | CD40 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGG SLRLSCA ASGY SFTGYYIHWVRQ APGKG LEWVARVI PNAGGTSYNQK F K GRFTLSVD NSKN TAYLQMN SLRAEDT AVYYCA REG IYWW GQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR SSQ SLVH SNGN TFLHWYQ QKPGKAP KLLIYTVS NRFSGVPS R FSGSGSGT DFTLTISS LQPED F ATYFC SQTTHVPW T FGQGT KVEI K |
Cilgavimab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLMYWASTRESGVPDRFSGSGSGAEFTLTISSLQAEDVAIYYCQQYYSTLTFGGGTKVEIK | na | na | 7l7e:CD:EF:MN:OP | null | null | 2,020 | 2021 | SARS-CoV-2 Spike RBD | AstraZeneca | COVID-19 | na | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFRDVWMSWVR QAPGKGL EWVGRIKSK IDGGTTDYAAP VKGRFTISR DDSKN TLYLQMN SLKTEDT AVYYCT TAGS YYYD TVGPGLPEGK FDY WGQG TLVTVS S | D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYS SNNKN YLAWYQ QKPGQPP KLLMYWAS TRESGVPDRFSGSGSGA EFTLTISS LQAED VAIYYCQ QYYS TLTF GGG TKVEI K |
Cinpanemab | Whole mAb | G1 | Lambda | Phase-II | Discontinued | EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS | SYELTQPPSVSVSPGQTARITCSGEALPMQFAHWYQQRPGKAPVIVVYKDSERPSGVPERFSGSSSGTTATLTITGVQAEDEADYYCQSPDSTNTYEVFGGGTKLTVL | na | na | 6ct7:HL:AB | null | null | 2,018 | 2019 | SNCA | Neurimmune Therapeutics;Biogen | na | na | Parkinson's disease | na | null | E VQLVES GGG LV EPGG SLRLSCAV SGFDFE KA WMSWVR QAPGQG LQWVARIKS TADGGT TSYA AP V EG RFIISR DDSRN MLYLQM NSLKTEDT AVYYCT SAHWGQG TLVTVS S | SYELTQPPS VSV SPGQ TARITC SGEALP MQFAHWYQ QRPGKAP VIVVYK DSERPSGVPE R FSGSSSGT TATLTITGVQ AEDEAD YYCQ SPDSTN TYEVF GGGT KLTV L |
Cinrebafusp | Fusion Protein | G4 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | na | na | 1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC | 1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC | 5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 2,019 | 2020 | ERBB2 | Eli Lilly and Company;Pieris Pharmaceuticals;Seagen | na | Gastic cancer;Solid tumours | na | na | Identical Fv sequence to Anvatabart, Coprelotamab, Trastuzumab, Timigutuzumab | E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Cirevetmab | Canine Whole mAb | G2 | Kappa | Unknown | Active | EVQLVQSGAEVKKPGASVKVSCKTSGYTFISSWMNWVRQAPGAGLDWMGQIYPGDGDTNYNGKFKGRVTLTADTSTSTAYMELSSLRAGDIAVYYCARHYDGSTDYWGQGTLVTVSS | EIVMTQSPASLSLSQGEKVTITCRASENIYSNLAWYQQRPGQAPKLLIYAATNLADGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHFWGTPYTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | TGFB1 (Canine) | TBC | TBC | TBC | TBC | TBC | null | E VQLVQ SGA EVK KPGA SVKVSC KTSG YTFIS SWMNWVR QAPGAGLD WMGQI YPGDGDTNYNG KFKGRVTLTA DTSTS TAYMELS SLRAGD IAVYYCARH YDGSTDY W GQ GTLVTVS S | E IVMT QSPA SLSL SQGE KVTITCR ASENIYSN LAWYQ QRPGQAP KLLIYAAT NLADGVPS RF SGSGSGTD FSLTIS SLEPED VAVYYCQH FWGTPY T FGQGT KLEI K |
Citatuzumab | Fab Fusion | G1 | Kappa | Phase-I | Discontinued | EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS | DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK | na | na | null | null | null | 2,008 | 2009 | EPCAM | Viventia Biotech;Sesen Bio | na | na | Solid tumours | na | null | E VQLVQ SGPG LV QPGG SVRISC AASGY TFTN YGM NWVK QAPGKGL EWMGWIN TYTGES TY ADSFKG RFTFSL DTSAS AAYLQINSL RAEDT AVYYCARFAIK GDYWGQ GTLLTVS S | DI QMT QSPSS LSA SVGD RVTITCR STK SLLH SNG ITYLYWYQ QKPGKAP KLLIYQM SNLASGVPS RF SSSGSGT DFTLTISS LQPE DF ATYYCA QNLEIPRTFGQGT KVEL K |
Cixutumumab | Whole mAb | G1 | Lambda | Phase-II | Discontinued | EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS | SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL | na | na | null | null | null | 2,008 | 2009 | IGF1R | Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA) | na | na | Breast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma | Dyax Human Phage Display | null | E VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RAP LRFLEW STQDH YYYYYMDV WGKG TTVTVS S | SSELTQDPA VSVA LGQ TVRITC QGDS LR SYYATWYQ QKPGQAP ILVIY GENKRPSGIPDRFSGSSSGN TASLTIT GAQAEDEA DYYCK SRDGSGQ HLVFG GGT KLTV L |
Clazakizumab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS | AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK | na | na | null | null | null | 2,012 | 2013 | IL6 | Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris | na | Renal transplant rejection;COVID-19 | Anaemia;Cachexia;Fatigue;Stomatitis;Crohn's disease;Graft-versus-host disease;Inflammation;Psoriatic arthritis;Rheumatoid Arthritis | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGFSLSN YYVTWVRQ APGKG LEWVGIIY GSDETA YAT S AIGRFTISR DNSKN TLYLQMNS LRAEDT AVYYCA RDDSSDWD AKFNLW GQG TLVTV SS | AI QMT QSPSS LSA SVGD RVTITCQ ASQSINNE LSWYQ QKPGKAP KLLIYRA STLASGVPS R FSGSGSGTD FTLTISS LQPDD F ATYYC QQGY SLRN IDNAFGGG TKVEI K |
Clervonafusp | di-Fab Fusion | G1 | Kappa | Phase-I/II | Active | EVQLQESGGGVVQPGGSLRLSCAASGFTFSNYGMHWIRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARRGLLLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTISCRASKSVSTSSYSYMHWYQQKPEKAPKLLIKYASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHSREFPWTFGAGTKLELK | na | na | null | null | null | 2,018 | 2019 | SLC29A2 | Valerion Therapeutics | na | Glycogen storage disease type II | na | na | (June '22: Corrected FWL2 and CDRL3 sequences) | E VQLQE SGG GVV QPGG SLRLSC AASGF TFS NYG MHWIRQ APGKGL EWVSYIS SGSS TIYYA DSVKG RFTISR DNSKN TLYLQMN SLRSEDT AVYYCA RRGL LLDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTISCR ASKSVSTSSY SYMHWY QQKPEKAP K LLIK YASYL QSGVPS RF SGSGSGTD FTLTIS SLQ PEDVA TYYC QHSREFPW TF GAGT KLEL K |
Clesrovimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVRPGRSLRLSCTVSGFSFDDSAMSWVRQAPGKGLEWISFIKSKTYGGTKEYAASVKGRFTISRDDSKNIAYLQMNSLKTEDTAVYYCTRGAPYGGNSDYYYGLDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRTSQDVRGALAWYQQKPGKAPKLLIFDASSLETGVPSRFSGSGSGTVFTLTISSLQPEDFAAYYCQQFLDFPFTFGQGTRLEIK | na | na | 6ous:MN:OP:QR:ST:UV:WX | null | null | 2,022 | na | RSV gpF | Merck Sharp & Dohme | na | Respiratory syncytial virus infections | na | na | null | E VQLVES GGG LV RPGR SLRLSCTVS G FS FDDSA MSWVRQ APGKGL EWISFIK SKTYGGTK EYAASVKGRFTIS RDDSKN IAYLQM NSLKTEDT AVYYCT RGAPYGGNSDY YYGLDV WGQG TTVTVS S | DIQMTQSPSS LSA SVGD RVTITCR TS QDVRGALAWYQQ KPGKAP KLLIFD ASSLETGVPSRFSGSGSG TVFTLTIS SLQ PEDFAAYYCQQF LDFPF T FGQGT RLEI K |
Clivatuzumab | Whole mAb Radiolabelled | G1 | Kappa | Phase-III | Discontinued | QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLYWYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGTDFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRLEIK | na | na | null | null | null | 2,009 | 2010 | MUC1 | Immunomedics | na | na | Pancreatic cancer | na | null | Q VQLQQ SGA EVK KPGA SVKVSCE ASGYTFPS YVLHWVK QAPGQG LEWIGYI NPYNDGTQYNE KF KG KATLT RDTSIN TAYMELSR LRSDDT AVYYCA RGFGGS YGFAYW GQG TLVTVS S | DI QLT QSPSS LSAS VGD RVTMTCS ASSSVSS SYLYWYQ QKPGKAP KLWIYS TSNLASGVP ARFS GSGSGT DFTLTISS LQPEDSA SYFCH QWNRYPYTFGGG TRLEI K |
Cobolimab | Whole mAb | G4 | Kappa | Phase-II/III | Active | EVQLLESGGGLVQPGGSLRLSCAAASGFTFSSYDMSWVRQAPGKGLDWVSTISGGGTYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYHQKPGKAPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQSHSAPLTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | HAVCR2 | AnaptysBio;GlaxoSmithKline;TESARO | na | Non-small cell lung cancer;Liver cancer;Malignant Melanoma | Solid tumours | na | null | E VQLLES GGG LV QPGG SLRLSCA AASGF TFSS YDM SWVR QAPGKGLD WVSTI SGGG TYTYYQ DSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCASM DYWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQ SIRRYLNWY HQKPGKAP KLLIYG ASTLQSGVPSRFSGSGSGTD FTLTIS SLQPED FAVYYC QQSHSAP LTF GGG TKVEI K |
Codrituzumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS | DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK | na | na | null | null | null | 2,013 | 2014 | GPC3 | Perseus Proteomics;Chugai Pharmaceutical;Roche | na | Liver cancer | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF TDY EMHWVRQ APGQG LEWMGAL DPKTGDTA Y SQKFKG RVTLTA DKSTS TAYMELS SLTSEDT AVYYCTRFYSYTY WGQG TLVTVS S | DV VMT QSPLSLPVTPGEPA SISC RSSQ SLVH SNRNT YLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYYCS QNTHVPPTFGQGT KLEI K |
Cofetuzumab | Whole mAb ADC | G1 | Kappa | Phase-I | Active | QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYAVHWVRQAPGKRLEWIGVISTYNDYTYNNQDFKGRVTMTRDTSASTAYMELSRLRSEDTAVYYCARGNSYFYALDYWGQGTSVTVSS | EIVLTQSPATLSLSPGERATLSCRASESVDSYGKSFMHWYQQKPGQAPRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNEDPWTFGGGTKLEIK | na | na | null | null | null | 2,017 | 2018 | PTK7 | Stemcentrx;Indiana University;Pfizer;Stemcentrx | na | Non-small cell lung cancer;Solid tumours | Breast cancer | na | null | Q VQLVQ SGPEVKKPGA SVKVSCK ASGY TFTDYAVHWVR QAPGK RLEWIGVISTY NDYTYNNQDFK GRVTMTR DTSAS TAYMELSR LRSEDT AVYYC ARGN SYFYALD YWGQG TSVTVS S | E IVLTQ SPA TLSL SPGE RATLSCRA SESVDSYGK SFMHWYQ QKPGQAP RLLIYRA SNLESGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QSNEDPW T FGGG TKLEI K |
Coltuximab | Whole mAb ADC | G1 | Kappa | Phase-II | Active | QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS | EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK | na | na | 6ani:HL:IM | null | null | 2,013 | 2014 | CD19 | ImmunoGen | na | Diffuse large B cell lymphoma | Precursor cell lymphoblastic leukaemia-lymphoma | na | null | Q VQLV QPGA EVV KPGA SVKLSC KTSG YTFT SN WMHWVK QAPGQGL EWIGEI DPSDSYTNYNQNFQG KAKLTVD KSTS TAYMEVSSL RSDDT AVYYCA RGSNP YYYAMD YWGQGT SVTVS S | E IVLT QSP AIMS ASPGE RVTMTCS ASSGV NYMHWYQ QKPGTSPR RWIYD TSKLASGVP ARFS GSGSGTD YSLTISS MEPEDAA TYYCH QRGS YTF GGG TKLEI K |
Conatumumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYFWSWIRQLPGKGLEWIGHIHNSGTTYYNPSLKSRVTISVDTSKKQFSLRLSSVTAADTAVYYCARDRGGDYYYGMDVWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQGISRSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPWTFGQGTKVEIK | na | na | 4n90:DE:FG:HI | null | null | 2,008 | 2009 | TNFRSF10B | Amgen;Takeda | na | na | Colorectal cancer;Lymphoma;Non-small cell lung cancer;Pancreatic cancer;Sarcoma;Solid tumours | Abgenix XenoMouse | null | QV QLQE SGPGLVKPSQ TLSLTCTV SGGSISSGD YFWSWIR QLPGKGL EWIGHIH NSGT TYY NPSLKS RVTISVD TSKK QFSLRLSS VTAADT AVYYCAR DRGGD YYYGMDV WGQG TTVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQGIS RS YLAWYQ QKPGQAP SLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QFGSSPWTFGQGT KVEI K |
Concizumab | Whole mAb | G4 | Kappa | Phase-III | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQTPEKRLEWVATISRSGSYSYFPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGGYDEGDAMDSWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIK | na | na | 4dtg:HL | null | null | 2,012 | 2013 | TFPI | Novo Nordisk | na | Haemophilia | na | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFS NY AMSWVR QTPEKR LEWVATIS RSGS YSY FPDSVQ GRFTISR DNAKNS LYLQMN SLRAEDT AVYYCAR LGGYDEGDAMDSWGQG TTVTVS S | DI VMT QTP LSLSV TPGQP ASISC KSSQ SLLE SDGK TYLNWYL QKPGQSPQ LLIYLVSI LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCLQAT HFPQTFGGG TKVEI K |
Coprelotamab | Whole mAb | G1 | Kappa | Preregistration | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | na | na | 1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC | 1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC | 5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 2,020 | 2021 | ERBB2 | Genor Biopharma | na | Breast cancer | na | Coprelotamab is a biosimilar of Trastuzumab and Timigutuzumab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains. | null | E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Cosfroviximab | Whole mAb | G1 | Kappa | Phase-II | Active | DVKLLESGGGLVQPGGSLKLSCAASGFSLSTSGVGVGWFRQPSGKGLEWLALIWWDDDKYYNPSLKSQLSISKDFSRNQVFLKISNVDIADTATYYCARRDPFGYDNAMGYWGQGTSVTVSS | DIVMTQSPLSLSTSVGDRVSLTCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELR | na | na | null | 5kel:CD:JN:MO/5kem:DE:IJ | null | 2,016 | 2017 | Zaire Ebolavirus GP | Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases | na | Ebola virus infections | na | Zmapp Technology | null | D VKLLES GGG LV QPGG SLKLSC AASG FSLS TSG VGVGWFR QPSGKGL EWLALIWW DDDKYYNPSLKS QLSIS KDFSRN QVFLKIS NV D IADT ATYYCAR RDPFGYDNAMG YW GQGT SVTVS S | D IVMT QSPL SLST SVGD RVSLTCK ASQNVG TAVAWYQ QKPGQSP KLLIYS ASNRYTGVPDRFTGSGSGTD FTLTIS NMQS EDLADYFCQQ YSSYP LTF GAGT KLEL R |
Cosibelimab | Whole mAb | G1 | Lambda | Phase-III | Active | EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAISWVRQAPGQGLEWMGVIIPAFGEANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRQMFGAGIDFWGQGTLVTVSS | NFMLTQPHSVSESPGKTVTISCTRSSGSIDSNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSNNRHVIFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | PDL1 | Dana-Farber Cancer Institute;Checkpoint Therapeutics;TG Therapeutics Inc | na | Cancer;Lymphoma | na | na | null | E VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSRSAISWVR QAPGQGL EWMGVIIP AFGEANYAQ K FQG RVTITA DESTS TAYMELS SLRSEDT AVYYC ARGR QMFG A GIDFW GQG TLVTVS S | NF MLT QPH SVS ESPGK TVTISCT RSSGSIDSN YVQWYQ QRPGSAP TTVIYE DNQRPSGVPDR FSGSI DSSSNS ASLTIS GLKTEDEAD YYCQSY DSNNR HVIFG GGT KLTV L |
Crefmirlimab | scFv Engineered Dimer | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHFVRQAPGKGLEWIGRIDPANDNTLYASKFQGKATISADTSKNTAYLQMNSLRAEDTAVYYCGRGYGYYVFDHWGQGTLVTVSS | DVQITQSPSSLSASVGDRVTITCRTSRSISQYLAWYQQKPGKVPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQQHNENPLTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | CD8A | ImaginAb | na | Solid tumours;Cervical cancer;Gastic cancer | Graft-versus-host disease | na | Uses G1 and CH3 region in the dimer | E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHFVRQ APGKG LEWIGRI DPANDN TLYAS KFQG KATISA DTSKN TAYLQMN SLRAEDT AVYYC GRGY GYYVFD HWGQG TLVTVS S | DV QIT QSPSS LSA SVGD RVTITCR TS RSISQYLAWYQ QKPGKVP KLLIYS GSTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDVATYYCQQ HNENPL T FGGGT KVEI K |
Crenezumab | Whole mAb | G4 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK | na | na | 5vzx:HL:EI/5vzy:HL | 5kmv:HL:EI | null | 2,011 | 2012 | APP | AC Immune;Genentech;Universidad de Antioquia | na | Alzheimer's disease | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LELVASIN SNGGS TY YPDSVK GRFTISR DNAKNS LYLQMNS LRAEDT AVYYC ASGDYWGQG TTVTVS S | DI VMT QSPLSLPVTPGEPA SISC RSSQ SLVYS NGD TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCS QSTHVPW T FGQGT KVEI K |
Crexavibart | Whole mAb | G1 | Lambda | TBC | Active | EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL | na | na | 7k90:HL:MN:OP | null | null | 2,022 | na | SARS-CoV-2 Spike RBD | TBC | TBC | COVID-19 | TBC | TBC | null | E VQLVES GGG LI QPGG SLRLSC AASGF TVS NN YMSWVR QAPGKGL EWVSVIYS GGS TYYA DSVKG RFTISR DKSKN TLYLQMNS LRAEDT AVYYCA REGE VEGY NDFWSGYSRD RYYFDY WGQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GTGT KVTV L |
Crizanlizumab | Whole mAb | G2 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | SELP | Selexys Pharmaceuticals;Novartis | Vaso-occlusive crisis | Priapism;Myelofibrosis;COVID-19 | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCKV SG YTFTSYDINWVR QAPGKGL EWMGWIY PGDGS IKY NEKFKG RVTMTVD KSTD TAYMELSS LRSEDT AVYYCAR RGEYGNYEGA M DYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQS V DYDGH SYMNWYQ QKPGKAP KLLIYAA SNLESGVPS R FSGSGSGTD FTLTISS LQPEDF ATYYCQ QSDENPL TF GGG TKVEI K |
Crotedumab | Whole mAb | G4 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYLMNWVRQAPGKGLEWLANIQEDGIEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREPSHYDILTGYDYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFILTVSSLQPEDFATYYCLQYNSNPFTFGPGTKVDIK | na | na | null | null | null | 2,015 | 2016 | GCGR | Regeneron Pharmaceuticals;Sanofi | na | na | Type 2 diabetes mellitus | na | null | E VQLVES GGG LV QPGG SLRLSC AASGFT FSNYLMNWVRQ APGKG LE WLAN IQEDGI EKYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REPSHYD IL TGYDY YY G MDV WGQG TTVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAPK RLIYAA SSLQSGVPS RF SGSGSGT EFILTVS SLQPEDF ATYYCLQY NSNPF T FGPGT KVDI K |
Crovalimab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK | na | na | 5b71:DC:BA | null | null | 2,018 | 2019 | C5 | Chugai Pharmaceutical;Roche | na | Atypical Haemolytic Uraemic Syndrome;Paroxysmal nocturnal haemoglobinuria | na | na | null | Q VQLVES GGG LV QPGR SLRLSC AASGF TVH SS YYMAWVRQ APGKGL EWVGAIFT GSGA EYKAEW AKG RVTISK DTSKN QVVLTMT NMDPVDT ATYYCA SDAGYDYPTH AMHYW GQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQGISS SLAWYQ QKPGKAP KLLIYG ASETESGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QNTKVGSSYGNTFGGG TKVEI K |
Cudarolimab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPWYSETGTSAFDIWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSDHYPTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | TNFRSF4 | Innovent Biologics | na | na | Solid tumours | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RGRPW Y SETGTS AFDI WGQG TMVTVS S | DIQMTQSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATY YC QQSDHYPTFGGGT KVEI K |
Cusatuzumab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSVYYMNWVRQAPGKGLEWVSDINNEGGTTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDAGYSNHVPIFDSWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGLKSGSVTSDNFPTWYQQTPGQAPRLLIYNTNTRHSGVPDRFSGSILGNKAALTITGAQADDEAEYFCALFISNPSVEFGGGTQLTVL | na | na | null | null | null | 2,017 | 2018 | CD70 | arGEN-X | na | Cutaneous T-cell lymphoma;Acute myeloid leukaemia;Haematological malignancies;Myelodysplastic syndromes;Solid tumours | Nasopharyngeal cancer;Autoimmune disorders | POTELLIGENT Technology;SIMPLE Antibody Technology | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSVYYMNWVR QAPGKG LEWVSD INNEGGT TYYAD SVKG RFTISR DNSKN SLYLQMN SLRAEDT AVYYCA RDAGYSNH VPIF DSWGQG TLVTVS S | QA VVT QEP SLTV SPGG TVTLTCGL KSGS V TSDNFPT WYQ QTPGQAP RLLIYN TNTRHSGVPDRFSG SI LGNK AALTIT GAQADDEA EYFCALFIS NPS VEF GGGT QLTV L |
Dacetuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK | na | na | null | null | null | 2,007 | 2008 | CD40 | Seattle Genetics | na | na | Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Multiple myeloma;Non-Hodgkin's lymphoma | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGY SFTGYYIHWVRQ APGKG LEWVARVI PNAGGTSYNQK F K GRFTLSVD NSKN TAYLQMN SLRAEDT AVYYCA REG IYWW GQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR SSQ SLVH SNGN TFLHWYQ QKPGKAP KLLIYTVS NRFSGVPS R FSGSGSGT DFTLTISS LQPED F ATYFC SQTTHVPW T FGQGT KVEI K |
Daclizumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK | na | na | 3nfs:HL/3nfp:HL:AB | null | null | 1,994 | 1998 | IL2RA | AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma | Renal transplant rejection | Multiple sclerosis | Asthma;Graft-versus-host disease;Haematological malignancies;Immune-mediated uveitis;Liver transplant rejection;Psoriasis;Tropical spastic paraparesis;Type 1 diabetes mellitus;Ulcerative colitis | GS Gene Expression System | Daclizumab is the new name for Dacliximab (PL78) | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTSYRMHWVRQ APGQG LEWIGYI NPSTGYTEYNQKFKDK ATITA DESTN TAYMELS SLRSEDT AVYYCA RGGG VFDY WGQG TLVTVS S | DIQ MT QSPS TLSAS VGD RVTITCS ASSS ISYMHWYQ QKPGKAP KLLIYTT SNLASGVP ARFS GSGSGT EFTLTISS LQPDDF ATYYCH QRSTYPL TF GQGT KVEV K |
Dafsolimab | Whole mAb | G2b | Kappa | Phase-III | Active | QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPSSGYTNYIQRFKDKATLTADKSSSTAYMQVSSLTSEDSAVYYCARGSRYDYYGMDYWGQGTSVTVSS | QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK | na | na | null | null | null | 2,020 | 2021 | CD3E | Xenikos | na | Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease | na | na | null | QV QLQ QSGA EL ARPGA SVKMSCK ASGY TFTSYTMHWVK QRPGQG LEWIGYI NPSSGYT NYIQR FKDK ATLTA DKSSST AYMQVSS LTSEDS AVYYC ARGS RYDY YGMDYWGQG TSVTVS S | Q IVLT QSP AIMS ASPGE KVTMTCS ASSS VSYMHWYQ QKSGTSPK RWIYD TSKLASGVP ARFS GSGSGT SYSLTISS MEAEDA A TYYCQQ WSSNPL TF GAGT KLEL K |
Dalnicastobart | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | CD40 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPDSGGTNY AQKF QG RVTMT RDTS ISTAYMEL NRLRSDDT AVYYCA RDQPLG Y CTNGV CSYFD YWGQG TLVTV SS | DIQ MT QSPSS VSAS VGD RVTITCR ASQG IY SWLAWY QQKPGKAPN LLIYT ASTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ ANIF PLTF GGG TKVEI K |
Dalotuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK | na | na | null | null | null | 2,009 | 2010 | IGF1R | Pierre Fabre;Merck & Co | na | na | Multiple myeloma;Neuroendocrine tumours;Non-small cell lung cancer;Solid tumours;Breast cancer;Colorectal cancer;Pancreatic cancer | na | Jain paper: "Entries in WHO-INN documents (PL102 and RL64) have errors" | QV QLQE SGPGL V KPSE TLSLTCTV SG YSI TGG YLWNWIR QPPGKGL EWIGYISY DGTNNYKPSLKD RVTISR DTSKN QFSLKLS SVTAADT AVYYCA RYG RVFFDY WGQG TLVTVS S | DI VMT QSPLSLPVTPGEPA SISC RSSQ SIVH SNGN TYLQWYL QKPGQSP QLLIYKV SNR LY GVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVPW TF GQGT KVEI K |
Dalutrafusp | Whole mAb Fusion | G1 | Kappa | Phase-I | Discontinued | EVQLVQSGAEVKKPGESLKISCKASGYAFSSSWINWVRQMPGKGLEWMGRIYPRAGDTNYAGKFKDQVTISADKSISTAYLQWSSLKASDTAMYYCASLLDYSMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPLTFGQGTKVEIK | na | na | null | null | null | 2,021 | 2022 | TGFBR2 | Gilead Sciences | na | na | Solid tumours | na | null | E VQLVQ SGA EVK KPGE SLKISCK ASGY AF S SSWINWVRQ MPGKGL EWMGRI YPRAGDTNYAGKFKD QVTIS ADKS ISTAYLQWS SLKASDT A MYYC ASLL DYSMDYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLHSGVPSRFSGSGSGTD FTFTIS SLQ PEDIA TYYC QQGN TLPLTF GQGT KVEI K |
Danburstotug | Whole mAb Fusion | G1 | Lambda | Phase-II | Active | QMQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAYSWVRQAPGQGLEWMGGIIPSFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGPIVATITPLDYWGQGTLVTVSS | SYVLTQPPSVSVAPGKTATIACGGENIGRKTVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCLVWDSSSDHRIFGGGTKLTVL | na | na | null | null | null | 2,022 | na | PDL1 | Sorrento Therapeutics;Asan Medical Center;ImmuneOncia Therapeutics | na | Extranodal NK-T-cell lymphoma;Gastric cancer;Liver cancer;Oesophageal cancer;Solid tumours | na | na | null | QM QLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAYSWVR QAPGQGL EWMGGII PSFGTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYC ARGP IVATIT PLDYWGQG TLVTVS S | SY VL TQPPS VSV APGK TATIAC GGENIGR KTVHWYQ QKPGQAP VLVIYY DSDRPSGIPERFSGSNSGN TATLTISRVE AGDEA DYYCLVWD SSSDH RIF GGGT KLTV L |
Danvilostomig | Bispecific Mixed mAb and scFv | G1;na | Kappa;Kappa | TBC | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCTASGFSLSSYAMSWVRQAPGKGLEYIGYIGDTTGIAYASWANGRFTISKDNTKNTVDLQMNSLRAEDTAVYYCARGWSYLDIWGQGTLVTVSS | ALVMTQSPSSLSASVGDRVTITCQASQNIYSNLAWYQQKPGKVPKLLIYQASTLASGVPSRFSGSGYGTDFTLTISSLQPEDVATYYCQGGYYSAALNTFGGGTKVEIK | 5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL;None | None;None | 7su0:HL:IM/7su1:HL;None | 2,022 | na | CTLA4;PDCD1 | TBC | TBC | TBC | TBC | TBC | Fv1 is Ipilimumab | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSYTMHWVRQ APGKGL EWVTFISY DGNNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AIYYCA RTGWLGPFDYWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCRA SQSVGS SYLAWYQ QKPGQAP RLLIYGAF SRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYGSSPW TF GQGT KVEI K |
Dapirolizumab | Fab | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAVSGFSSTNYHVHWVRQAPGKGLEWMGVIWGDGDTSYNSVLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARQLTHYYVLAAWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASEDLYYNLAWYQRKPGKAPKLLIYDTYRLADGVPSRFSGSGSGTDYTLTISSLQPEDFASYYCQQYYKFPFTFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | CD40LG | Biogen;Biogen Idec;UCB | na | Systemic lupus erythematosus;Multiple sclerosis | Amyotrophic lateral sclerosis;Rheumatoid Arthritis | na | null | E VQLVES GGG LV QPGG SLRLSCAV SGFSSTN YHVHWVRQ APGKG LEWMGVIW GDGDTSYNS VLKSRFTISR DTSKN TVYLQMNS LRAEDT AVYYCA RQLT HYYVLAAW GQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASEDL YYNLAWYQ RKPGKAP KLLIYDTYR LADGVPS RF SGSGSGTD YTLTISS LQ PEDFASYYCQ QYYKFPF T FGQGT KVEI K |
Daratumumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK | na | na | 7dun:HL/7duo:HL/7dha:CB | null | null | 2,009 | 2010 | CD38 | Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals | Multiple myeloma | Amyloid light-chain amyloidosis;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor T-cell lymphoblastic leukaemia-lymphoma;Prostate cancer;T-cell lymphoma;Waldenstrom's macroglobulinaemia;Solid tumours | Non-small cell lung cancer | Medarex HuMAb Mouse | null | E VQLLES GGG LV QPGG SLRLSCAV SGF TF NS FAMSWVR QAPGKGL EWVSAIS GSGGG TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYFC AKDK ILWF GEP VF DYWGQG TLVTV SS | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPTFGQGT KVEI K |
Dargistotug | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGSELKKPGASVKVSCKASGYTFTSYPMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARVGGYSVDEYAFDVWGQGTLVTVSS | DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLSSYPTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | TIGIT | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGS E LKKPGA SVKVSCK ASGY TFTS YPMN WVR QAPGQGL EWMGWIN TNTGNPTYAQG FTGRFVFSL DTSVS TAYLQISS LKAEDT AVYYCARV GG YS VDE YAFDVW GQG TLVTVS S | DI QLT QSPS FLSA SVGD RVTITCR ASQG ISSYLAWYQ QKPGKAP KLLIYAA STLQSGVPS R FSGSGSGT EFTLTIS SLQ PEDFATYYCQQ LSSYPTFGGGT KVEI K |
Datopotamab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARSGFGSSYWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | TACSTD2 | Daiichi Sankyo | na | Breast cancer;Non-small cell lung cancer | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTT AG MQWVRQ APGQGL EWMGWIN THSGVPKYAEDFKG RVTISA DTSTS TAYLQLS SLKSEDT AVYYCA RSGFGSS YWYFDV WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASQD VST AVAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTLTIS SLQP ED FAVYYC QQHYITP LTF GQGT KLEI K |
Daxdilimab | Whole mAb | G1 | Lambda | Phase-II | Active | QVQLQQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTIDTSTSTAYMELRSLRSDDTAVYYCARNGLWGWDSDAFDIWGRGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL | na | na | null | null | null | 2,020 | 2021 | LILRA4 | Viela Bio | na | Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma;Acute lung injury | na | na | null | Q VQLQQ SGA EVK KPGA SVKVSCK ASGY TFTSYGISWVRQ APGQGL EWMGWISAY NGNTNY AQK LQG RVTMTID TSTST AYMELRSL RSDDT AVYYCA RNGLWGWDSDAF DIW GRG TLVTV SS | QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCS SYTSSS TVVF GGGT KVTV L |
Dectrekumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLWFGDLDAFDIWGQGTMVTVSS | EIVLTQSPATLSLSPGERAILSCRAGQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPPVYTFGQGTKLEIK | na | na | null | null | null | 2,014 | 2015 | IL13 | Novartis | na | na | Asthma;Idiopathic pulmonary fibrosis;Keloids;Oesophagitis;Rectal fistula;Seasonal allergic rhinitis | na | null | E VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAIIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARLW FGDLDA FDI WGQG TMVTVS S | E IVLT QSPA TLSL SPGE RAILSCR AGQS VSSYLVWYQ QKPGQAP RLLIYD ASNRATG I P ARF SGSGSGT DFTLTIS SLEPED FAVYYCQ QRSSWPP VYTF GQGT KLEI K |
Delpacibart | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | TFRC | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYWMHWVR QAPGQG LEWIGEI NPINGRSNYAEKFQG RVTLTVD TSSST AYMELSR LRSDDT AVYYC ARGT RAMHYW GQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR TSEN IYNNLAW YQ QKPGKSP KLLIYAAT NLADGVPS RF SGSGSGTD YTLTIS SLQ PEDFATY Y CQH FWGTPL TF GGG TKVEI K |
Demcizumab | Whole mAb | G2 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK | na | na | null | null | null | 2,012 | 2013 | DLL4 | Celgene Corporation;OncoMed Pharmaceuticals | na | na | Colorectal cancer;Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKISCK ASGY SFTAYYIHWVK QAPGQG LEWIGYISS YNGATNYNQ KFKGRVTFTT DTSTS TAYMELRSL RSDDT AVYYCAR DYDYDVGMDYWGQG TLVTVS S | D IVMT QSPDS LAVS LGER ATISCR ASESVDNYG ISFMK W F QQKPGQPP KLLIYAA SNQGSGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QQSKEVPW T FGGG TKVEI K |
Demupitamab | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS | DIQMTQSPSTLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK | na | na | null | 5sx4:HL:JI/5sx5:HL:JK | null | 2,019 | 2020 | EGFR | Sinocelltech | na | Cancers | na | na | Likely to be a Panitumumab biosimilar | Q VQLQE SGPGL V KPSE TLSLTCTVS GGSVSSGD YYWTWIRQ SPGKGL EWIGHIYYS GNTNYNPSLK SRLTISID TSKT QFSLKLSS VTAADT AIYYCVR DRVTG AFDIW GQG TMVTVS S | DIQMTQSPS TLSAS VGD RVTITCQ AS QDISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYFCQH FDHLP LAF GGGT KVEI K |
Denicimig | Bispecific mAb | G4;G4 | Kappa;Kappa | TBC | Active | EVQLVESGGGLVQPGRSLRLSCAASGFTFHDYAMHWVRQVPGKGLEWVSGISWRGDIGGYVKSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKSYGSGSFYNAFDSWGQGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKFLIYKASKLERGTPSRFSGSGSGTEFSLTISSLQPDDFATYYCLEYSSYIRTFGQGTKVEIK | EVQLVQSGAEVKKPGESLRISCKGSGYSFSTSWIVWVRQMPGKGLEWMGMIDPSDSFTSYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARLHYYNSEEFDVWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGQSSRTRGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSQLFTFGQGTKLEIK | null | 7ahv:AB | null | 2,022 | na | F9;F10 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGR SLRLSC AASGF TFH DY AMHWVRQ VPGKGL EWVSGISWR GDIGG YVKSV K GRFTISR DNAKN SLYLQMNS LRAEDT ALYYCVKS YGSGS FYN AFDSWGQG TLVTV SS | DIQ MT QSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KFLIYK ASKLERGTPS RF SGSGSGT EFSLTIS SLQPDDF ATYYCLE YSS YIRTF GQGT KVEI K |
Denintuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIK | na | na | null | null | null | 2,014 | 2015 | CD19 | Seattle Genetics | na | na | Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma | na | null | Q VQLQE SGPGLVKPSQ TLSLTCTV SGGS IS TSGM GVGWIRQ HPGKGL EWIGHIWW DDDKRYNPALK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCARMELWSYYFD YWGQG TLVTV SS | E IVLTQ SPA TLSL SPGE RATLSCS ASSS VSYMHWYQ QKPGQAP RLLIYD TSKLASGIP ARFS GSGSGT DFTLTISS LEPED VAVYYCF QGS VYPFT FGQGT KLEI K |
Denosumab | Whole mAb | G2 | Kappa | Approved | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK | na | na | null | null | null | 2,005 | 2006 | TNFSF11 | Amgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network | Bone cancer;Bone disorders;Bone metastases;Corticosteroid-induced osteoporosis;Male osteoporosis;Malignant hypercalcaemia;Osteoporosis;Postmenopausal osteoporosis;Rheumatoid arthritis | Breast cancer;Non-small cell lung cancer;Osteogenesis imperfecta;Malignant melanoma | Multiple myeloma | Abgenix XenoMouse | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVSGI TGSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA KDPGT TVIMSWF DPWGQ GTLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVRG RYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVFYCQ QYGSSPRTFGQGT KVEI K |
Depatuxizumab | Whole mAb ADC | G1 | Kappa | Phase-III | Discontinued | QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDFAWNWIRQPPGKGLEWMGYISYSGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGRGFPYWGQGTLVTVSS | DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK | na | na | null | null | null | 2,016 | 2017 | EGFR | Ludwig Institute for Cancer Research;AbbVie | na | na | Solid tumours | na | null | Q VQLQE SGPGLVKPSQ TLSLTCTV SG YSI SSDF AWNWIR QPPGKGL EWMGYISY SGNTRYQPSLK SRITISR DTSKN QFFLKLN SVTAADTA TYYCVT AGRGFPYWGQ GTLVTVS S | DIQ MT QSPSS MSVS VGD RVTITCH SSQDINSN IGWLQ QKPGKS FKGLIYH GTNLDDGVPS RF SGSGSGTD YTLTISS LQPEDF ATYYCVQYA QFPWTFGGGT KLEI K |
Depemokimab | Whole mAb | G1 | Kappa | Phase-III | Active | QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSGLLRLDYWGRGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK | na | na | null | null | null | 2,020 | 2021 | IL5 | GlaxoSmithKline | na | Asthma | na | na | null | Q VTLRE SGPA LV KPTQ TLTLTCTV SG FSL TGS SVHWVR QPPGKGL EWLGVIWA SGGTDYNS A LMSRLSIS KDTSRN QVVLTMT NMDPVDT ATYYCA RDPPSG LLRLDY WGRG TLVTVS S | D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSGNQ KNYLAWYQ QKPGQPP KLLIYG ASTRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNVHSFP FTF GGGT KLEI K |
Derlotuximab | Whole mAb Radiolabelled | G1 | Kappa | Approved | Active | QVQLKESGPGLVAPSQSLSITCTVSGFSLTDYGVRWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKEKRRGYYYAMDYWGQGTSVTVSS | ENVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGGGTKLEIK | na | na | null | null | null | 2,015 | 2016 | DNA/H1 Complex | Avid Bioservices;MediPharm Biotech | Lung cancer | Glioblastoma | na | na | null | QV QLKE SGPGL V APSQ SLSITCTV SGF SL TDY GVRWIR QPPGKGL EWLGVIW GGGST YY NSALK SRLSI SKDNSKS QVFLKM NSLQTDDT AMYYCA KEKRRG YYYAMD YWGQGT SVTVS S | ENVLTQSP AIMS ASPGE KVTMTCR ASSSVSS SYL HWYQ QKSGASP KLWIYS TSNLASGVP ARFS GSGSGT SYSLTISS VE A E DAAT YYC QQ YSGYP LTF GGGT KLEI K |
Devextinetug | Whole mAb | G2 | Kappa | TBC | Active | EIQLQQSGPELGKPGASVKVSCRASGFSFADYYIYWVKQSHGKSLELIGYIDPFNGGDTYNQIFKGKATLTVDKSSSTAFMYLNSLTSEDSAVYYCAAFRNPSFDFWGQGTTLTVSS | QIVLIQSPPIMSASPGEKVTLTCSASSSVSSRYLYWYQQKPGSSPKLWIYGTSNLASGVPARFSGSGSGTSFSLTISSMEAEDAASYFCHQWSSFPFTFGSGTKLEIK | na | na | null | null | null | 2,022 | na | Metamphetamine | TBC | TBC | TBC | TBC | TBC | null | E IQLQQ SGPELGKPGA SVKVSCR ASGFSFA DYYIYWVK QSHGK SLELIGYI DPFNGGDTY NQIF KG KATLTV DKSSS TAFMYLN SLTSEDS AVYYCAAF RNPSFD F WGQG TTLTVS S | Q IVLIQ SPP IMS ASPGE KVTLTCS ASSSVSS RYLYWYQ QKPGSSP KLWIYG TSNLASGVP ARFS GSGSGT SFSLTISS MEAED AASY FC HQWSSFP FTF GSGT KLEI K |
Dezamizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIHNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGAPLTFGQGTKLEIK | na | na | null | null | null | 2,016 | 2017 | APCS | Pentraxin Therapeutics;GlaxoSmithKline | na | na | Amyloidosis | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGF TFATYNMHWVRQ APGQG LEWMGYIY PGDGNANYNQQ F K GRVTITA DKSTS TAYMELS SLRSEDT AVYYCA RGDFDYDGG YYF DSWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASEN IYSYLAWY QQKPGKAP KLLIH NAK TL AEGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YCQ HHYGAP LTF GQGT KLEI K |
Dilpacimab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFPMAWVRQAPGKGLEWVATISSSDGTTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYYNSPFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASEDIYSNLAWYQQKPGKAPKLLIYDTNNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPPTFGQGTKLEIK | EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK | None;1bj1:HL:KJ | None;None | None;6bft:HL:AB/1cz8:HL:YX | 2,018 | 2019 | DLL4;VEGFA | AbbVie | na | Colorectal cancer;Solid tumours | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SNFP MAWVRQ APGKG LEWVATIS SSDGT TYYRD SVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA RGYYNSPF AYW GQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASED IYSNLAWYQ QKPGKAP KLLIYD TNNLADGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YNNYPPTFGQGT KLEI K |
Dinutuximab | Whole mAb | G1 | Kappa | Approved | Active | EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS | EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK | na | na | null | null | 4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:AB:CD/4tuk:HL | 2,013 | 2014 | Ganglioside GD2 | National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation | Neuroblastoma | Small cell lung cancer | Malignant melanoma | na | null | E VQLLQ SGPELEKPGA SVMISCK ASGSSFTGYN MNWVRQ NIGKS LEWIGAI DPYYGGTSYNQKFKG RATLTVD KSSS TAYMHLKS LTSEDS AVYYCV SGM EY WGQG TSVTVS S | E IVMT QSPA TLSV SPGE RATLSCR SSQ SLVHR NGN TYLHWYLQ KPGQSP KLLIHKV SNRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GVYFCS QSTHVPPL TF GAGT KLEL K |
Diridavumab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLVESGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGPEWMGGIIPIFGTTKYAPKFQGRVTITADDFAGTVYMELSSLRSEDTAMYYCAKHMGYQVRETMDVWGKGTTVTVSS | QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEANYYCATWDRRPTAYVVFGGGTKLTVL | na | na | 3gbn:HL/3gbm:HL:IM/5c0s:HL/6uyn:HL | null | 4evn:AB:CD:IJ:OP:KL:EF:GH:MN | 2,014 | 2015 | Influenza A HA2 | National Institute of Allergy and Infectious Diseases;Crucell | na | Influenza A virus (H1N1) infections | na | na | null | E VQLVE SGA EVK KPGS SVKVSCK ASGGPF RSYAISWVR QAPGQGPEW MGGIIPIF GTTKYAPKFQG RVTITA DDFAG TVYMELS SLRSED TAMYYCAKH MGY QVRETMDV WGKG TTVTVS S | QSVLTQPPSVSAAPGQ KVTISC SGSSSNIGND YVSWYQ QLPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS ATLGITG LQTGDEA NYYCAT WDRRP TAYVVF GGGT KLTV L |
Disitamab | Whole mAb ADC | G1 | Kappa | Approved | Active | EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYYNQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | ERBB2 | Yantai Rongchang Biological Engineering | Gastric cancer | Breast cancer;Urogenital cancer;Non-small cell lung cancer;Cholangiocarcinoma;Lung cancer | Solid tumours | na | null | E VQLVQ SGA EVK KPGA TVKISCKV SGY TFTDYYIHWVQQ APGKG LEWMGRV NPDHGDSYYNQKFKDK ATITA DKSTDT AYMELS SLRSEDT AVYFCA RN YLF DHWGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCK ASQDVG TAVAWYQ QKPGKAP KLLIYWASIR HTGVPSRFSGSGSGTD FTLTISS LQPEDF ATYYCHQFATYTF GGG TKVEI K |
Divozilimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVQPGAEVVKPGASVKVSCKASGYTFTSYNMHWVRQAPGRGLEWMGAIYPGNGDTSYNQKFKGRVTMTRDKSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTLVTVSS | QIVLSQSPAILSASPGERVTLTCRASSSVSYIHWFQQKPGKAPKPLIYATSNLASGVPSRFSGSGSGTDFSLTISRVEPEDFAVYYCQQWTSNPPTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | MS4A1 | Biocad | na | Relapsing-remitting multiple sclerosis | na | na | null | E VQLV QPGA EVV KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGRG LEWMGAI YPGNGDTSYNQK FKGRVTMTR DKSTS TVYMELS SLRSEDT AVYYCAR S T YYGGD WYFNVW GQG TLVTVS S | Q IVLS QSP AILS ASPGE RVTLTCR ASSS VSYIHWFQ QKPGKAPKP LIYAT SNLASGVPS R FSGSGSGT DFSLTISR VEPED FAVYYCQQW TSNPPTFGGG TKVEI K |
Docaravimab | Whole mAb (Mouse) | G2b | Kappa | Approved | Active | QVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS | DVQMTQTTSSLSASLGDRVTITCRPSQDINNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPPTFGGGTKLEIK | na | na | null | null | null | 2,019 | 2020 | Rabies Virus Strain ERA GP Ectodomain Epitope G-III | Candila Healthcare | Rabies | na | na | na | Mouse antibody | Q VQLKE SGPGLLAPSQ SLSITCTV SG FSLTG H GVNWVR QPPGKGL EWLGIIWA DGTTNYNSAL KSRLSI SKDNSKS QVFLKM NSLQTDDTA SYYCA REGD I S GYYFDY WGQG TTLTVS S | DVQM TQ TTS SLSA SLGD RVTITC RPSQD INNYLSWYQ QKPDGT VKLLIYYT SRLHSGVPSRFSGSGSGTD YSLTIS NLEQE DFATY FC QQGNTLPPTFGGGT KLEI K |
Domagrozumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDYAMNYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK | na | na | null | 5f3h:EF:GH:AB:CD | null | 2,015 | 2016 | MSTN | Kennedy Krieger Institute;Pfizer | na | na | Duchenne muscular dystrophy;Limb girdle muscular dystrophies | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSTI SSGGS Y TSYPDSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KQDYAMNYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASQD VSTA VAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QHYSTPW T FGGG TKVEI K |
Domvanalimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAFISSGSSSIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARMRLDYYAMDYWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCRASKSISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPWTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | TIGIT | Arcus Biosciences | na | Solid tumours;Non-small cell lung cancer | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFS NF GMHWVRQ APGKG LEWVAFIS SGSS SIYYA DTVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARMRLDYYAM DYWGQG TMVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR ASKS ISKYLAWYQ QKPGKAP KLLIYS GSTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QHNEYPW T FGGGT KVEI K |
Donanemab | Whole mAb | G1 | Kappa | Preregistration | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYDFTRYYINWVRQAPGQGLEWMGWINPGSGNTKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAREGITVYWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSRGKTYLNWLLQKPGQSPQLLIYAVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGTHYPFTFGQGTKLEIK | na | na | null | null | null | 2,018 | 2019 | APP | Eli Lilly | na | Alzheimer's disease | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGYDF TRYYINWVR QAPGQGL EWMGWI NPGSGNTKYNEKFKG RVTITA DESTS TAYMELS SLRSEDT AVYYCA REG ITVYW GQGT TVTVS S | DI VMT QTP LSLSV TPGQP ASISC KSSQ SLLYS RGK TYLNWLL QKPGQSP QLLIYAVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCV QGTHYPF TF GQGT KLEI K |
Dostarlimab | Whole mAb | G4 | Kappa | Approved | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS | DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK | na | na | null | null | null | 2,018 | 2019 | PDCD1 | AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO | Endometrial cancer;Solid tumours | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Non-small cell lung cancer;Breast cancer;Cervical cancer;Liver cancer;Malignant melanoma;Neuroendocrine tumours;Pancreatic cancer;Rectal cancer;Small cell lung cancer;Squamous cell cancer | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSS YDM SWVR QAPGKG LEWVSTI SGGGS YTYYQ DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA SPYY AM DYWGQG TTVTVS S | DI QLT QSPS FLSAY VGD RVTITCK ASQDVG TAVAWYQ QKPGKAP KLLIYWA STLHTGVPSRFSGSGSGT EFTLTIS SLQP EDFA TYYCQ HYSSYPW T FGQGT KLEI K |
Dovanvetmab | Feline Whole mAb | G1 | Kappa | Unknown | Active | QVLLVQSGAEVRTPGASVKIFCKASGYSFTSYTIHWLRQAPAQGLEWMGNINPTSGYTENNQRFKDRLTLTADTSTNTAYMELSSLRSADTAMYYCARWGFKYDGEWSFDVWGAGTTVTVSS | EIQMTQSPSSLSASPGDRVTITCRASQGISIWLSWYQQKPGNIPKVLINKASNLHIGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCLQSQTYPLTFGGGTKLEIK | na | na | null | null | null | 2,019 | 2020 | IL31 (Feline) | na | na | na | na | na | null | Q VLLVQ SGA EVR TPGA SVKIFCK ASGYS FTSYTIHWLR QAPAQGL EWM GNINPTSGYTENNQRFKD RLTLTA DTSTN TAYMELS SLRS ADTAMYYCAR WGFKYDG EWSFDVW GAGT TVTVS S | EI QMT QSPSSL S ASPGD RVTITCR ASQG ISIWLSWY QQKPGNIP KVLIN KASN LHIGV PSRFSGSGSGT DFTLTISS LEPEDAA TYYCL QSQTYP LTF GGGT KLEI K |
Dresbuxelimab | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLVQSGAEVVKPGASVKVSCKASGYSFTGYTMNWVRQAPGQNLEWIGLINPYNAGTSYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARSEYRYGGDYFDYWGQGTTLTVSS | DIVMTQSPSSLAVSVGERVTISCKSSQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYDTPYTFGGGTKLEIK | na | na | null | null | null | 2,021 | 2022 | NT5E | Akeso Biopharma | na | COVID-19 | na | na | null | Q VQLVQ SGA EVV KPGA SVKVSCK ASGY SFTGYTMNWVR QAPGQN LEWIGLI NPYNAGTSYNQK F QG KVTLTVD KSTS TAYMELSS LRSEDT AVYYCAR SE YR YGGD YF DYWGQG TTLTVS S | D IVMT QSPSS LAVS VGE RVTISC KSSQS L LNSSNQK N YLAWYQ QKPGQAP KLLIYFA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QHYDTPY T FGGGT KLEI K |
Drozitumab | Whole mAb | G1 | Lambda | Phase-II | Discontinued | EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS | SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL | na | na | 4od2:BA | null | null | 2,010 | 2011 | TNFRSF10B | Genentech | na | na | Chondrosarcoma;Colorectal cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer | na | null | E VQLVQS GGG VE RPGG SLRLSC AASGFTFDD YA MSWVR QAPGKGL EWVSGIN WQGGSTGYADSVKG RVTISR DNAKN SLYLQMN SLRAED TA VYY CAKI L GAGRG WYFDY WGKG TTVTVS S | SELTQDPA VSV A LGQ TVRITC SGD SLRSYYASWY QQKPGQAP VLVIY GANNRPSGIPDRFSGSSSGNT ASLTIT GAQAEDEAD YYC NSADSSGN HVVF GGGT KLTV L |
Duligotuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK | na | na | null | null | 3p0v:HL:IM/3p0y:HL/3p11:HL | 2,012 | 2014 | ERBB3 | Genentech;Roche | na | na | Solid tumours;Colorectal cancer;Head and neck cancer | na | Duligotuzumab is the new name for Duligotumab (PL110) | E VQLVES GGG LV QPGG SLRLSC AASG FTL SGD WIHWVRQ APGKGL EWVGEIS AAGGYTDYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCA RESR VSFEAAM DYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQNIA TDVAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQPE DF ATYYCQ QSEPEPY T FGQGT KVEI K |
Dupilumab | Whole mAb | G4 | Kappa | Approved | Active | EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK | na | na | 6wgb:AB:CD/6wgj:AB:CD:EF/6wgk:AB:CD:EF:GH/6wgl:AB/6wg8:AB | null | null | 2,012 | 2013 | IL4R | Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi | Asthma;Atopic dermatitis;Nasal polyps | Chronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria | Allergic asthma | VelocImmune Mouse | null | E VQLVE SGGGLEQPGG SLRLSC AGSGF TFRDYAMTWVRQ APGKG LEWVSSIS GSGGN TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC AKDR LSITIR PR Y YG LDVW GQG TTVTVS S | DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLYSI G YNYLDWYLQK SGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GFYYCMQA LQTPY T FGQGT KLEI K |